Fertility Assessment in Patients With Klinefelter Syndrome

July 20, 2018 updated by: Kyle Orwig, University of Pittsburgh

Non-Invasive Methods to Maximize Fertility in Peri-Pubertal Patients With Klinefelter Syndrome

Klinefelter syndrome is characterized by primary testicular failure and progressive infertility. The objective of this study is to determine if sperm are present and can be observed in semen samples of adolescent and young adult Klinefelter patients and to determine whether the presence of sperm correlates with physical and/or clinically obtained hormone measures of pubertal development.

This study was designed in order to answer the following questions:

  1. Is it possible to retrieve sperm for cryopreservation from semen samples of adolescent and young adult Klinefelter patients?
  2. Does the presence of sperm correlate with the physical and/or endocrine measures that are assessed during routine clinical evaluations of pubertal development in the KS patient population?
  3. If sperm retrieval is possible, what is the optimal age at which sperm retrieval should be attempted?

Study Overview

Status

Terminated

Intervention / Treatment

Detailed Description

Klinefelter Syndrome (KS) is a genetic condition in boys and men that results from having two X chromosomes and one Y chromosome. The incidence of the 47, XXY karyotype that defines the disorder ranges from 1:500 to 1:1000 in newborn males. The sexual development and fertility phenotypes of Klinefelter's syndrome include azoospermia (absence of sperm in the ejaculate), small firm testes, gynaecomastia (enlargement of breast tissue), low testosterone levels, and elevated follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels that can have an important impact on the quality of life for these patients. Beginning with puberty, testicular biopsies from Klinefelter patients progressively show a degenerated testicular environment with Sertoli-cell-only tubules, sclerotic or hyalinized tubules, and interstitial Leydig cell hyperplasia. Nevertheless, scattered areas with focal spermatogenesis can be seen in Klinefelter men, and assisted reproductive techniques now offer hope for patients who wish to father their own biological children. In these cases, a surgical sperm recovery procedure called testicular sperm extraction (TESE) is performed to extract sperm for in vitro reproductive methods. Success rates for testicular sperm extraction in Klinefelter patients are consistently above 50% (50 - 72%) and are similar to the success rates reported for TESE in azoospermic patients without Klinefelter syndrome. Pregnancy rates and life births after intracytoplasmic sperm injection (ICSI) are similar in couples with or without KS, and babies fathered by KS patients have a normal karyotype. Previous studies in adult KS patients reported that sperm recovery rates were significantly lower after the age of 35. Therefore, it was suggested that surgical sperm recovery in younger (possibly pubertal) boys should be considered as an option to maximize the opportunity to preserve their fertility before becoming sterile. However, there is considerable debate about the benefit of early invasive fertility intervention for KS patients.

The standard, non-invasive and safe way to obtain and analyze sperm production and quality in normal post-pubertal males is to obtain a semen sample by masturbation. It is currently unknown when spermatogenesis starts in boys with KS, and if sperm could be detected by semen analysis in early puberty. In this proposal, the investigators aim to determine if non-invasive methods during puberty could be useful to assess the reproductive potential of KS patients, and to possibly cryopreserve sperm from these patients for future use with well-established assisted reproductive techniques like in vitro fertilization with ICSI (intra cytoplasmic sperm injection).

Although this will be a sensitive topic for adolescent patients with KS and their parents, it is essential to begin the conversation regarding fertility preservation. Indeed, most parents and patients have questions regarding future fertility. This study has a secondary benefit in that it provides an ideal opportunity to educate the affected males and their families about the long-term effects of KS on their fertility and the availability of reproductive technologies to help with fertility. Similar discussions are becoming increasingly common (standard of care) for cancer patients who are at risk for infertility due to their disease or oncologic treatment.

It is currently unknown when spermatogenesis starts in boys with KS. While it seems to be commonly accepted that there is a progressive depletion of germ cells in the testes of KS patients after the onset of puberty, the data to support this notion are equivocal due to small patient populations, lack of controls and absence of longitudinal data.

In addition, the standard therapy for boys with KS is testosterone replacement therapy to trigger entry and progression of puberty characterized by the development of secondary sexual characteristics, bone maturation, and continued linear growth. However, testosterone supplementation also suppresses spermatogenesis (if present) through negative feedback on the hypothalamus-pituitary-gonadal axis. Some argue that any intervention to preserve fertility for KS patients should ideally precede hormone replacement therapy. However, in one study it was proposed that topical testosterone therapy might not negatively affect spermatogenesis in adolescent KS patients. The risks and unknowns of invasive surgical procedures like TESE for boys have to be carefully weighed against the possible benefits for this unique patient population. For these reasons, the investigators propose that non-invasive methods would be appropriate to retrieve sperm and are essential to gain insights about the initiation and decline of spermatogenesis in KS patients.

In this study, the investigators will analyse if sperm can be found in semen of Klinefelter patients during puberty and early adulthood. Participants will be followed until they reach age 26. During the time of their study participation, participants will provide at least one semen sample.

Study Type

Observational

Enrollment (Actual)

6

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15224
        • Children's Hospital of Pittsburgh of UPMC
      • Pittsburgh, Pennsylvania, United States, 15213
        • Magee-Womens Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 21 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

Adolescent and young adults males who are proven to have Klinefelter Syndrome based on prior chromosome analysis (47,XYY).

Description

Inclusion Criteria:

  • males between the ages of 12 and 25
  • diagnosed with mosaic or non-mosaic Klinefelter's Syndrome
  • having bilaterally descended testes
  • not having had a febrile illness within 3 months of enrollment.

Exclusion Criteria:

  • previous treated with gonadotoxic chemotherapeutic or radiation regimen.
  • psychological, psychiatric, or other conditions which prevent giving fully informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Other

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Presence of sperm in semen.
Time Frame: On average once a year until the participant turns 26

Participants will provide at least one semen sample. The presence of sperm will be analyzed.

Participants will also be given the opportunity to have their semen analysed for the presence of sperm once a year.

Participants will be followed until they reach age 26.

On average once a year until the participant turns 26

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Longitudinal correlation of developmental and endocrine parameters with the presence or absence of sperm in semen samples.
Time Frame: 1 time a year for an average of 7.4 years
Participants will be followed until they reach age 26. Thereafter, patients will be contacted once a year via phone to asses fertility/infertility issues and over all health.
1 time a year for an average of 7.4 years
Correlation of developmental parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will measure height.

1-2 times a year for an average of 7.4 years
Correlation of developmental parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will measure weight.

1-2 times a year for an average of 7.4 years
Correlation of developmental parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will measure body proportions.

1-2 times a year for an average of 7.4 years
Correlation of developmental parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will measure Tanner stages.

1-2 times a year for an average of 7.4 years
Correlation of developmental parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will examine the presence of gynecomastia.

1-2 times a year for an average of 7.4 years
Correlation of developmental parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will measure and bilateral testicular size.

1-2 times a year for an average of 7.4 years
Correlation of endocrine parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will measure testosterone (T).

1-2 times a year for an average of 7.4 years
Correlation of endocrine parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will measure luteinizing hormone (LH)

1-2 times a year for an average of 7.4 years
Correlation of endocrine parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will measure follicle-stimulating hormone (FSH).

1-2 times a year for an average of 7.4 years
Correlation of endocrine parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will measure serum anti-Mullerian hormone (AMH).

1-2 times a year for an average of 7.4 years
Correlation of endocrine parameters with the presence or absence of sperm in semen samples.
Time Frame: 1-2 times a year for an average of 7.4 years

Participants will be scheduled for a routine visit with the endocrinologist 1-2 times a year.

At each visit, the endocrinologist will measure inhibin B.

1-2 times a year for an average of 7.4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kyle Orwig, PhD, University of Pittsburgh

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 7, 2016

Primary Completion (Actual)

December 12, 2017

Study Completion (Actual)

December 12, 2017

Study Registration Dates

First Submitted

May 26, 2015

First Submitted That Met QC Criteria

May 29, 2015

First Posted (Estimate)

June 3, 2015

Study Record Updates

Last Update Posted (Actual)

July 24, 2018

Last Update Submitted That Met QC Criteria

July 20, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Klinefelter Syndrome

Clinical Trials on Counseling

Subscribe